Abstract：Objective To investigate the distribution and drug resistance of multidrug resistance of
Acinetobacter baumannii in Western China, and provide evidence for the rational use of antibiotics and prevention and control of nosocomial infections. Methods We retrospectively analyzed the isolation, distribution, and drug
resistance of multidrug-resistant Acinetobacter baumannii in the bacterial cultures of ten top-three hospitals in Western
China from 2016 to 2017. WHONET 5.6 software was used in data analysis and drug susceptibility analysis. Results
8,847 strains of Acinetobacter baumannii were detected in the tested strains from 2016 to 2017, and the detection rate
was 7.43%. Among them, 5,768 strains of Acinetobacter baumannii with multidrug resistance were detected, and the
detection rate was 4.84%. 65.20% of strains of Bacillus were multi-drug resistant Acinetobacter baumannii which
were mainly isolated from sputum specimens (80.97%), secretions (6.12%), and blood (2.08%), and were distributed
to the intensive care unit (14.6%), the emergency department (11.94%), and the department of respiratory diseases
(11.62%). Among the patients with multidrug-resistant Acinetobacter baumannii, the largest number of patients
was over 70 years old, a total of 1,688 cases (29.26%), which was significantly more than other age groups. The multidrug
resistance rates of Acinetobacter baumannii were generally higher than others to 12 commonly used antibiotics.
The resistance rates to seven species were over 90%. The lowest resistance rate was 55.7%, which was to amikacin,
followed by bumycin (67.40%) and compound sulfamethoxazole (68.25%). Conclusion The multidrug resistance of
Acinetobacter baumannii in Western China is still very serious. Particularly, carbapenem-resistant drug-resistant bacteria,
and its distribution and drug resistance were significantly different compared with other regions. Amikacin should be
firstly considered for the treatment of multidrug resistant Acinetobacter baumannii infections, followed by cotrimoxazole
and tobramycin. All hospitals in this region should strengthen monitoring and supervising the clinical rational use
of antibiotics based on the drug susceptibility in order to reduce the occurrence of multidrug resistant Acinetobacter
baumannii. In addition, laboratories in hospitals should further strengthen analytical research of the multidrug resistant
Acinetobacter baumannii to provide more scientific and effective laboratory data for clinics and hospitals.
阿祥仁 李子安,* 周健武 魏莲花 徐修礼 贾伟 喻华 单斌 季萍 鲁卫平 张华 郭素芳. 中国西部地区多重耐药鲍曼不动杆菌的耐药及分布特点[J]. 中国抗生素杂志, 2018, 43(9): 1138-1142.
A Xiang-ren,Li Zi-an,Zhou Jian-wu,Wei Lian-hua,Xu Xiu-li,Jia Wei,Yu Hua,Shan Bin,
Ji Ping,Lu Wei-ping,Zhang Hua and Guo Su-fang. The multidrug resistance of Acinetobacter baumannii in Western China and its
distribution characteristics. CJA, 2018, 43(9): 1138-1142.
